FDA Approves First-of-its-Kind Drug for Polycythemia Vera (Rusfertide/Mimrylo)
Key claim: The FDA approved rusfertide (Mimrylo), the first hepcidin-mimetic drug, for adults with polycythemia vera not adequately controlled by existing therapies.
Abstract
The Food and Drug Administration recently approved rusfertide (Mimrylo, Takeda) as a new treatment for adults with polycythemia vera whose disease is not adequately controlled with existing therapies. Rusfertide is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that regulates iron availability in the body.
Why this matters
Rusfertide’s approval formally establishes hepcidin mimicry as an approved therapeutic axis in PV, alongside phlebotomy, hydroxyurea, interferons, and JAK inhibitors — directly addressing the well-documented real-world gap in maintaining HCT <45% with standard of care. It validates the broader iron-restriction pipeline (sapablursen, DISC-3405) that has dominated recent PV natural-history-modifying trial activity and gives clinicians a first non-cytoreductive option targeting the erythrocytosis biology specific to this subtype.